ATE399026T1 - Zusammensetzungen enhaltend l-typ- calciumcanalblockern und cholinesterase-hemmern - Google Patents
Zusammensetzungen enhaltend l-typ- calciumcanalblockern und cholinesterase-hemmernInfo
- Publication number
- ATE399026T1 ATE399026T1 AT04811351T AT04811351T ATE399026T1 AT E399026 T1 ATE399026 T1 AT E399026T1 AT 04811351 T AT04811351 T AT 04811351T AT 04811351 T AT04811351 T AT 04811351T AT E399026 T1 ATE399026 T1 AT E399026T1
- Authority
- AT
- Austria
- Prior art keywords
- type calcium
- blockers
- canal
- compositions containing
- cholinesterase inhibitors
- Prior art date
Links
- 239000000544 cholinesterase inhibitor Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title 1
- 229910052791 calcium Inorganic materials 0.000 title 1
- 239000011575 calcium Substances 0.000 title 1
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 abstract 2
- 229940122041 Cholinesterase inhibitor Drugs 0.000 abstract 1
- 101000953562 Dendroaspis angusticeps Kunitz-type serine protease inhibitor homolog calcicludine Proteins 0.000 abstract 1
- 101000723297 Dendroaspis polylepis polylepis Calciseptin Proteins 0.000 abstract 1
- -1 compound (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate Chemical class 0.000 abstract 1
- 229960003530 donepezil Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52366403P | 2003-11-21 | 2003-11-21 | |
| US60811604P | 2004-09-09 | 2004-09-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE399026T1 true ATE399026T1 (de) | 2008-07-15 |
Family
ID=34636482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04811351T ATE399026T1 (de) | 2003-11-21 | 2004-11-19 | Zusammensetzungen enhaltend l-typ- calciumcanalblockern und cholinesterase-hemmern |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US20050153953A1 (de) |
| EP (3) | EP1684806B1 (de) |
| JP (2) | JP2007512338A (de) |
| AT (1) | ATE399026T1 (de) |
| AU (2) | AU2004292966A1 (de) |
| CA (2) | CA2546395A1 (de) |
| DE (1) | DE602004014635D1 (de) |
| ES (1) | ES2309594T3 (de) |
| WO (2) | WO2005051426A1 (de) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040122090A1 (en) * | 2001-12-07 | 2004-06-24 | Lipton Stuart A. | Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
| AU2004256237B2 (en) | 2003-07-09 | 2007-08-23 | Shell Internationale Research Maatschappij B.V. | Tool for excavating an object |
| US7445058B2 (en) | 2003-10-21 | 2008-11-04 | Shell Oil Company | Nozzle unit and method for excavating a hole in an object |
| CN100545412C (zh) | 2003-10-29 | 2009-09-30 | 国际壳牌研究有限公司 | 流体喷射钻具 |
| US8058291B2 (en) | 2005-04-06 | 2011-11-15 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of CNS-related conditions |
| US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
| WO2006058236A2 (en) | 2004-11-24 | 2006-06-01 | Neuromolecular Pharmaceuticals, Inc. | Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease |
| ATE526965T1 (de) * | 2005-04-15 | 2011-10-15 | Res & Innovation S P A | Verfahren zur prävention, verzögerung oder umkehr von abnormer amyloid-ablagerung |
| WO2007003941A1 (en) * | 2005-07-06 | 2007-01-11 | Cambridge Enterprise Limited | Modulation of autophagy by calpain inhibition |
| WO2008109343A1 (en) * | 2007-03-01 | 2008-09-12 | Memory Pharmaceuticals Corporation | Methods of treating bipolar disorder and memory and/or cognitive impairment associated therewith with (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate |
| US8580776B2 (en) * | 2007-07-10 | 2013-11-12 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating neurodegenerating diseases |
| WO2009051922A1 (en) * | 2007-10-15 | 2009-04-23 | Memory Pharmaceuticals Corporation | Methods of treating alzheimer's disease with (+) - isopropyl 2-methoxyethyl 4-(2-chloro-3- cyano-phenyl) -1, 4-dihydro-2, 6-dimethyl-pyridine-3, 5-dicarboxylate and a cholinesterase inhibitor |
| JP2011518783A (ja) * | 2008-04-09 | 2011-06-30 | コンサート ファーマシューティカルズ インコーポレイテッド | ３−（２−ヒドロキシ−５−メチルフェニル）−ｎ，ｎ−ジイソプロピル−３−フェニルプロピルアミンの誘導体およびその使用方法 |
| US20100137403A1 (en) * | 2008-07-10 | 2010-06-03 | Scott Malstrom | Method for enhancing cognition or inhibiting cognitive decline |
| EP3345905B1 (de) * | 2008-09-18 | 2021-09-01 | Auspex Pharmaceuticals, Inc. | Deuterierte benzochinolizinderivate als inhibitoren des vesikulären monoamintransporters 2 |
| WO2010077730A2 (en) * | 2008-12-09 | 2010-07-08 | Auspex Pharmaceutical, Inc | Indanone inhibitors of acetylcholinesterase |
| US9968574B2 (en) | 2009-05-15 | 2018-05-15 | The University Of Kentucky Research Foundation | Treatment of MCI and Alzheimer's disease |
| JP2012526844A (ja) * | 2009-05-15 | 2012-11-01 | ザ ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション | Ｍｃｉおよびアルツハイマー病の処置 |
| US8741343B2 (en) | 2009-12-02 | 2014-06-03 | Adamas Pharmaceuticals, Inc. | Method of administering amantadine prior to a sleep period |
| WO2011142778A1 (en) * | 2010-05-13 | 2011-11-17 | The University Of Kentucky Research Foundation | Treatment of mci and alzheimer's disease |
| US9550780B2 (en) | 2012-09-18 | 2017-01-24 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| EP2897615A4 (de) | 2012-09-18 | 2016-04-27 | Auspex Pharmaceuticals Inc | Pharmakokinetikformulierungen von deuterierten benzochinolinhemmern des vesikel-monoamin-transporters 2 |
| US10154971B2 (en) | 2013-06-17 | 2018-12-18 | Adamas Pharma, Llc | Methods of administering amantadine |
| EP3424504A1 (de) | 2013-12-03 | 2019-01-09 | Auspex Pharmaceuticals, Inc. | Verfahren zur herstellung von benzochinolinverbindungen |
| WO2016144901A1 (en) | 2015-03-06 | 2016-09-15 | Auspex Pharmaceuticals, Inc. | Methods for the treatment of abnormal involuntary movement disorders |
| IL260290B2 (en) | 2015-12-30 | 2023-11-01 | Corium Inc | Systems and methods for long-term percutaneous administration |
| US20210161890A1 (en) * | 2015-12-31 | 2021-06-03 | Bach Pharma, Inc. | Compositions and methods for treating brain dysfunction |
| WO2018009256A1 (en) | 2016-03-29 | 2018-01-11 | Respirerx Pharmaceuticals, Inc. | Compositions and methods for treating attention deficit disorders |
| US11541018B2 (en) | 2016-06-23 | 2023-01-03 | Corium, Llc | Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent |
| JP7153010B2 (ja) | 2016-07-27 | 2022-10-13 | コリウム， インコーポレイテッド | 塩薬物のｉｎ ｓｉｔｕでの塩から中性の薬物変換による、低溶解度または不安定非イオン化中性薬物の経皮配合物および送達方法 |
| CN109789134A (zh) | 2016-07-27 | 2019-05-21 | 考里安国际公司 | 与口服递送药代动力学生物等效的透皮递送系统 |
| MX2019001104A (es) | 2016-07-27 | 2019-10-02 | Corium Int Inc | Sistemas de suministro transdermico de memantina. |
| KR102904873B1 (ko) | 2017-07-26 | 2025-12-29 | 코리움, 엘엘씨 | 용매가 채워진 공극을 가진 미세다공성 막을 구비한 경피 전달 시스템 |
| CA3086163A1 (en) | 2017-12-20 | 2019-06-27 | Corium, Inc. | Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point |
| CA3206935A1 (en) * | 2021-01-29 | 2022-08-04 | 3Z Ehf | Novel treatments |
| WO2024136579A1 (ko) * | 2022-12-22 | 2024-06-27 | 서울대학교산학협력단 | 도파민 생성 억제제 또는 도파민 수용체 길항제를 포함하는 인지기능 장애의 예방, 개선 또는 치료용 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EE03192B1 (et) * | 1993-12-10 | 1999-06-15 | Bayer Aktiengesellschaft | Isopropüül-(2-metoksüetüül)-4-(2-kloro-3-tsüanofenüül)-1,4-dihüdro-2,6-dimetüülpüri diin-3,5-dikarboksülaat, selle enantiomeerid ja vaheühend, meetodid nimetatud ühendite valmistamiseks ja kasutamine |
| ES2293638T3 (es) * | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
| US6334997B1 (en) * | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US5698224A (en) * | 1994-06-27 | 1997-12-16 | Alza Corporation | Tacrine therapy |
| JP4332902B2 (ja) * | 1997-04-25 | 2009-09-16 | 味の素株式会社 | 新規ジヒドロピリジン誘導体 |
| US6979698B1 (en) * | 1997-08-11 | 2005-12-27 | Targacept, Inc. | Method of treating cognitive deficits in learning and memory |
| KR20010033442A (ko) * | 1997-12-22 | 2001-04-25 | 에가시라 구니오 | 신규 디하이드로피리딘 유도체 |
| US6440967B1 (en) * | 1998-11-12 | 2002-08-27 | Merck & Co., Inc. | Combination of a GABAA alpha 5 inverse agonist and COX-2 inhibitor, NSAID, estrogen or vitamin E |
| US20040024043A1 (en) * | 2002-03-22 | 2004-02-05 | Nigel Greig | Method for treating cognitive disorders |
| WO2004034963A2 (en) * | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
-
2004
- 2004-11-19 CA CA002546395A patent/CA2546395A1/en not_active Abandoned
- 2004-11-19 AT AT04811351T patent/ATE399026T1/de not_active IP Right Cessation
- 2004-11-19 EP EP04811351A patent/EP1684806B1/de not_active Expired - Lifetime
- 2004-11-19 ES ES04811351T patent/ES2309594T3/es not_active Expired - Lifetime
- 2004-11-19 WO PCT/US2004/038623 patent/WO2005051426A1/en not_active Ceased
- 2004-11-19 JP JP2006541354A patent/JP2007512338A/ja active Pending
- 2004-11-19 AU AU2004292966A patent/AU2004292966A1/en not_active Abandoned
- 2004-11-19 AU AU2004292967A patent/AU2004292967A1/en not_active Abandoned
- 2004-11-19 WO PCT/US2004/038624 patent/WO2005051389A1/en not_active Ceased
- 2004-11-19 CA CA002546366A patent/CA2546366A1/en not_active Abandoned
- 2004-11-19 DE DE602004014635T patent/DE602004014635D1/de not_active Expired - Fee Related
- 2004-11-19 EP EP08153319A patent/EP1952824A1/de not_active Withdrawn
- 2004-11-19 US US10/992,464 patent/US20050153953A1/en not_active Abandoned
- 2004-11-19 US US10/580,008 patent/US20080026081A1/en not_active Abandoned
- 2004-11-19 EP EP04811352A patent/EP1684755A1/de not_active Withdrawn
- 2004-11-19 JP JP2006541355A patent/JP2007512339A/ja active Pending
-
2008
- 2008-10-30 US US12/261,649 patent/US20090069361A1/en not_active Abandoned
-
2009
- 2009-02-20 US US12/389,576 patent/US20090156639A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1684806A1 (de) | 2006-08-02 |
| WO2005051389A1 (en) | 2005-06-09 |
| EP1952824A1 (de) | 2008-08-06 |
| EP1684755A1 (de) | 2006-08-02 |
| JP2007512339A (ja) | 2007-05-17 |
| CA2546395A1 (en) | 2005-06-09 |
| US20050153953A1 (en) | 2005-07-14 |
| US20080026081A1 (en) | 2008-01-31 |
| AU2004292967A1 (en) | 2005-06-09 |
| DE602004014635D1 (de) | 2008-08-07 |
| AU2004292966A1 (en) | 2005-06-09 |
| WO2005051426A1 (en) | 2005-06-09 |
| US20090069361A1 (en) | 2009-03-12 |
| JP2007512338A (ja) | 2007-05-17 |
| ES2309594T3 (es) | 2008-12-16 |
| US20090156639A1 (en) | 2009-06-18 |
| CA2546366A1 (en) | 2005-06-09 |
| EP1684806B1 (de) | 2008-06-25 |
| AU2004292967A2 (en) | 2005-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE399026T1 (de) | Zusammensetzungen enhaltend l-typ- calciumcanalblockern und cholinesterase-hemmern | |
| ATE453393T1 (de) | Verwendung von pyridylamiden als angiogenesehemmer | |
| ATE510534T1 (de) | Naltrexonhydrochlorid-zusammensetzungen | |
| DE60324544D1 (de) | Muskarin antagonisten | |
| DK1499184T3 (da) | Sammensætninger til behandling af ektoparasitangreb | |
| NO20062561L (no) | Kinoliner nyttige for behandling av kardiovaskulaere sykdommer | |
| ATE515277T1 (de) | Zusammensetzungen und verfahren zum beschichten von medizinischen implantaten | |
| DK1596880T3 (da) | Fremgangsmåder og sammensætninger til undertrykkelse af fibrocytdifferentiering | |
| IS7718A (is) | Pýrrólídíndíónútskipt píperídín-þalasón sem PDE4 tálmar | |
| IS6950A (is) | Samsetning epóþílonhliðstæðna og efnameðferðarlyfja til meðhöndlunar frumufjölgunarsjúkdóma | |
| MX342071B (es) | Formas polimorficas de 3-(4-amino-1-oxo-1, 3 dihidro-isoindol-2-il )-piperidin-2, 6-diona. | |
| DK2298338T3 (da) | Lactoferrin-sammensætninger og fremgangsmåder til behandling af hudsår | |
| EP1628530A4 (de) | Verfahren und zusammensetzungen zur vorbeugung und behandlung von sepsis | |
| DE50115252D1 (de) | Substituierte glutarimide und ihre verwendung als inhibitoren der il-12 produktion | |
| CY1117051T1 (el) | Φαρμακευτικες συνθεσεις που περιεχουν κρυσταλλικη μορφη (i) της υδροχλωριουχου λερκανιδιπινης | |
| DK1789419T3 (da) | Gyraseinhibitorer og anvendelser deraf | |
| DK1132570T3 (da) | Sammensætninger til syrebehandling af borebrönde | |
| UA88463C2 (ru) | Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции | |
| NO20062256L (no) | Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner | |
| PT1536796E (pt) | Bifenilcarboxamidas com substituintes n-arilo piperidina como inibidoras da secreção da apolipoproteína b | |
| DE60329326D1 (de) | Tace inhibitoren | |
| ATE359283T1 (de) | Substituierte pyrazinonverbindungen zur behandlung von entzündungen | |
| AU2003259202A8 (en) | Compositions and methods for treating and preventing infection | |
| WO2008106659A3 (en) | Methods of treating bipolar disorder and memory and/or cognitive impairment associated therewith | |
| DE60117783D1 (de) | Naphthamidin-urokinasinhibitoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |